Home›Clinical trials›Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

A study testing whether a GLP-1 medicine, semaglutide, can help people protect their kidneys.

Recruiting now. Registry record last updated June 2, 2026.

Who can join
Adults 18+, have diabetic kidney disease, BMI 20+.
What you take
semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 3.7 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor University of WashingtonDrug semaglutideClass GLP-1 RASites 3 USEnrollment target 60

What this study is for

Primary condition: Diabetic Kidney Disease. Also studied in: Type 1 Diabetes.

Full scientific study title: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes.

Who can join

Age18 and upSexAnyBMI20 or higher

Adults 18+, have diabetic kidney disease, BMI 20+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Adults (≥18 years) with type 1 diabetes
  • Diabetes duration of ≥5 years
  • Persistent urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g, on the most recent two measurements within the prior 3 years
  • Estimated glomerular filtration rate ≥ 20 mL/min/1.73m2
  • Stable doses of drugs altering blood pressure (e.g., Angiotensin-converting enzyme inhibitor) required for at least 4 weeks prior to randomization, and requested for the duration of the trial

Key exclusion criteria

  • HbA1c \>9%, recent diabetic ketoacidosis, hyperosmolar hyperglycemic state or severe illness requiring hospitalization in past 30 days
  • Other causes of diabetes mellitus, including type 2 diabetes and maturity-onset diabetes of the young (MODY)
  • Chronic kidney disease unrelated to diabetes
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or thyroid nodule palpated by endocrinologist at screening
  • Personal history of pancreatitis

Where this trial is enrolling

This trial has 3 sites across 2 states. Contact a site coordinator directly to start screening.

Colorado1 site
Washington2 sites

Timeline

Started enrolling: April 5, 2024. Expected completion: December 2027. Last updated on ClinicalTrials.gov: June 2, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.